RxDoctor Payments Data

Pamela Simmons, MD

Family Medicine · Temecula, CANPI 1508828310

Payments from drug & device makers

$1,175in general payments, 2019–2025

Across 40 payments — averaging $29.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$291
  • Novo Nordisk$256
  • Abbott$139
  • Boston Scientific$135
  • Baxter Healthcare$109
  • GSK$83
  • plus $161 from 7 others

What the payments were for

  • Food & beverage$1,06691%
  • Other$1099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,175 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$60,245
Medicare patients
170
Services billed
590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide50$49,927
FarxigaDapagliflozin Propanediol78$49,579
OzempicSemaglutide43$41,025
JardianceEmpagliflozin28$35,317
EliquisApixaban30$33,214
XareltoRivaroxaban11$15,574
TrulicityDulaglutide12$14,992
EntrestoSacubitril/Valsartan15$13,436
Spiriva RespimatTiotropium Bromide24$12,194
Levothyroxine Sodium251$3,859
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,449
Atorvastatin Calcium356$3,162
Bupropion XlBupropion Hcl97$1,909
Pregabalin51$1,752
Ezetimibe61$1,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$256$90,95293 claims
AstraZenecaFarxiga$291$49,57978 claims
Lilly USA, LLCTrulicity$14$14,99212 claims
NovartisEntresto$23$13,43615 claims
AbbVieSynthroid$53$1,13827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →